Spark R F, Dale S L, Kahn P C, Melby J C
J Clin Invest. 1969 Jan;48(1):96-104. doi: 10.1172/JCI105978.
Angiotensin infusion evokes marked increases in aldosterone secretion in primary aldosteronism and little change in secondary aldosteronism. The low plasma renin activity of primary aldosteronism and the elevated plasma renin activity of secondary aldosteronism are thought to account for this differential response. The effect of angiotensin on aldosterone and 18-hydroxycorticosterone secretion was studied during adrenal vein catheterization in seven patients with primary aldosteronism (whose plasma renin activity had been elevated following spironolactone therapy), one hypertensive patient with normal plasma renin activity and normal aldosterone secretion, two patients with secondary aldosteronism who had elevated plasma renin activity, and one anephric patient whose plasma renin activity was 0. Adrenal venous aldosterone and 18-hydroxycorticosterone were measured before and after a ten min sub-pressor angiotensin infusion. The cells of the aldosterone-producing adenoma (APA) respond to small increases in plasma angiotensin with large increases in secretion of aldosterone and 18-hydroxycorticosterone. The dose of angiotensin capable of evoking this response from the aldosterone-producing adenoma produces little or no change in the secretion of the steroids from nontumorous glands. The augmentation of aldosterone secretion, induced by angiotensin, in primary aldosteronism is due solely to increased secretion by the adenoma and not by the contralateral zona glomerulosa. The increased sensitivity of the aldosterone-producing adenoma is characteristic of the tumor. This response is independent of fluctuations in endogenous plasma renin activity. This sensitivity is not blunted by high plasma renin activity, nor is it a function of tumor mass for the effect is observed in aldosterone-producing adenomas regardless of size. ACTH injection after angiotensin infusion resulted in a marked increase in aldosterone concentration in the effluent from the nontumorous adrenal, but was not capable of producing further increases in aldosterone concentration in the effluent from the APA. In view of this exquisite sensitivity to infused angiotensin, it may be that the small variations in endogenous plasma renin activity that have been observed in primary aldosteronism may be capable of evoking large changes in aldosterone secretion in patients with aldosterone-producing adenomas.
在原发性醛固酮增多症中,输注血管紧张素可引起醛固酮分泌显著增加,而在继发性醛固酮增多症中变化不大。原发性醛固酮增多症患者血浆肾素活性低,继发性醛固酮增多症患者血浆肾素活性升高,被认为是导致这种差异反应的原因。在7例原发性醛固酮增多症患者(螺内酯治疗后血浆肾素活性已升高)、1例血浆肾素活性正常且醛固酮分泌正常的高血压患者、2例血浆肾素活性升高的继发性醛固酮增多症患者和1例血浆肾素活性为0的无肾患者进行肾上腺静脉插管期间,研究了血管紧张素对醛固酮和18 - 羟皮质酮分泌的影响。在输注10分钟低于升压剂量的血管紧张素前后,测量肾上腺静脉中的醛固酮和18 - 羟皮质酮。产生醛固酮的腺瘤(APA)细胞对血浆血管紧张素的小幅增加会产生醛固酮和18 - 羟皮质酮分泌的大幅增加。能够从产生醛固酮的腺瘤引发这种反应的血管紧张素剂量,对非肿瘤性腺分泌的类固醇几乎没有影响或没有影响。在原发性醛固酮增多症中,血管紧张素诱导的醛固酮分泌增加完全是由于腺瘤分泌增加,而非对侧球状带。产生醛固酮的腺瘤敏感性增加是该肿瘤的特征。这种反应与内源性血浆肾素活性的波动无关。这种敏感性不会因高血浆肾素活性而减弱,也不是肿瘤大小的函数,因为无论大小,在产生醛固酮的腺瘤中都观察到了这种效应。血管紧张素输注后注射促肾上腺皮质激素(ACTH)导致非肿瘤性肾上腺流出物中醛固酮浓度显著增加,但不能使APA流出物中醛固酮浓度进一步增加。鉴于对输注血管紧张素的这种高度敏感性,原发性醛固酮增多症中观察到的内源性血浆肾素活性的微小变化可能能够引起产生醛固酮的腺瘤患者醛固酮分泌的大幅变化。